Abstract:The detection of bisphosphonates is important due to the potential integrity and welfare issues associated with use of these substances. Targeted detection of a nitrogenous and non‐nitrogenous bisphosphonate was detected for 8 h and 28 days post‐administration, respectively. With this, the need for complementary indirect detection using lipid and corticosteroid biomarkers was investigated. Putative biomarkers were identified, which are now subject to validation into routine analysis for improved detection capabilities of bisphosphonate misuse in equine plasma. Detecting the use of bisphosphonates (BPs) in equine athletes is of interest to regulators and laboratories due to the threat to welfare issues for the potential to provide analgesic effects and manipulating bone structure. The detection of BPs in biological matrices is challenging due to erratic biological elimination and inconsistent analytical recoveries. Therefore, complementary approaches are needed to provide evidence of their misuse in racehorses. BPs have two sub‐classes: nitrogenous and non‐nitrogenous. This study investigated plasma elimination following administration of one example from each sub‐class, together with changes in endogenous eicosanoid and corticosteroids. Zoledronic acid (ZA) and tiludronic acid (TA) were administered by IV infusion to 8 thoroughbred horses with an 11‐month washout period between each administration. Sample preparation for quantification of BPs by liquid chromatography–tandem mass spectrometry (LC–MS/MS) utilised a two‐step solid phase extraction (SPE) consisting of polymeric reversed‐phase followed by weak anion exchange prior to derivatisation using trimethyl orthoacetate. Endogenous biomarkers were analysed after protein precipitation and SPE with polymeric reversed‐phase prior to liquid chromatography–high resolution mass spectrometry (LC‐HRMS) using data independent acquisition. The LC–MS/MS analysis showed ZA was undetectable after 8 h post‐administration while TA was detected up to the final collection point of 28 days post‐administration. The LC‐HRMS analysis utilised targeted (i.e., prior inclusion list of compounds) approaches to monitor level changes of eicosanoid and corticosteroid biomarkers. Putative biomarkers were identified and now subject to validation for translation into routine sample analysis for improved retrospectivity to detecting BP misuse in equine plasma.

Pharmacokinetic study of osilodrostat and identification of mono‐hydroxylated metabolite in equine plasma for the purpose of doping control

Metabolic Pathway of Osilodrostat in Equine Urine Established through High-resolution Mass Spectrometric Characterization for Doping Control

Quantification of osilodrostat in horse urine using LC/ESI-HRMS to establish an elimination profile for doping control

Detection of FG‐4592 and metabolites in equine plasma, urine and hair following oral administration

Investigation Into the Equine Metabolism of Phosphodiesterase‐4 Inhibitor Roflumilast for Potential Doping Control

Rapid investigating of phase I metabolites of SR9009 in vitro horse liver microsomes via feature-based molecular networking approach: Potential applications in doping control

Detection of methandienone and its metabolites in equine urine, plasma and hair following a multidose oral administration

A steroidomic approach for biomarkers discovery in doping control

Doping control analysis of myo‐inositol trispyrophosphate and 10 bisphosphonates in equine plasma by ion chromatography–mass spectrometry and its application to clodronic acid horse administration

Detection of the selective androgen receptor modulator S-23 and its metabolites in equine urine and plasma following oral administration

Broad‐spectrum and sensitive screening of more than 1000 compounds in equine urine using liquid chromatography/high‐resolution mass spectrometry

A Broad-Spectrum Peptide Screening Method Using an Optimized Solid-Phase Extraction and Liquid Chromatography–High-Field Asymmetric Ion Mobility Spectrometry–Mass Spectrometry for Doping Control in Equine Urine

Identification and differentiation of somapacitan, a long-acting growth hormone derivative, and recombinant human growth hormone in equine plasma by LC-HRMS for doping control purpose

Non-Targeted Detection of Synthetic Oligonucleotides in Equine Serum Using Liquid Chromatography–High-Resolution Mass Spectrometry

Lipid and Corticosteroid Biomarkers Under the Influence of Bisphosphonates

Development and validation of general plasma screening method for performance enhancing drugs in racehorses utilizing liquid chromatography-high-resolution mass spectrometry (LC-HRMS)

Detection of Over 110 Anabolic–Androgenic Steroids, Corticosteroids and/or Their Esters in Horse Hair Using Ultra‐High‐Performance Liquid Chromatography–High‐Resolution Mass Spectrometry and Gas Chromatography–Tandem Mass Spectrometry After Solid‐Supported Liquid Extraction

Detection of nonsteroidal and steroidal selective androgen receptor modulators in equine hair after oral administrations

3-Methoxytyrosine as an indicator of dopaminergic manipulation in equine plasma

Analysis of loxoprofen in tablets, patches, and equine urine as tert-butyldimethylsilyl derivative by gas chromatography-mass spectrometry